Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.
from...
'Pharma's exemption from reciprocal tariffs underscores generic medicines' critical role globally'
The US Administration has exempted pharmaceuticals from reciprocal tariffs, highlighting the significance of affordable, life-saving generic medicines. The decision supports the vital trade partnership between India and the US, with Indian pharmaceutical companies supplying a substantial proportion of drugs to American residents and generating significant...
Big relief for India! Trump spares pharma from harsh tariffs
US President Trump has exempted India's pharmaceuticals from new reciprocal tariffs, benefiting the major export industry. This exemption highlights the significance of India's cost-effective generic medicines in US healthcare. The White House noted that removing trade barriers in other sectors could increase US exports by $5.3 billion annually.
from...
Fortis healthcare buys disputed Fortis trademark for Rs 200 crore
Fortis Healthcare has acquired the Fortis trademark from its former promoters, the Singh brothers, for Rs. 200 crore through a court-sanctioned auction. The trademark was involved in a litigation case with Japan's Daiichi Sankyo. Fortis Healthcare, now owned by IHH Healthcare, operates a network of 26 hospitals nationwide.
from Healthcare/Biotech-Industry-Economic...
Lupin acquires UK-based firm for 12.3 million pounds
Lupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to expand in the UK market with Renascience's products for infectious diseases, ear pain, and cardiovascular and renal treatment. This move supports Lupin's mission to provide accessible healthcare solutions.
from...
Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.
from Healthcare/Biotech-Industry-Economic...
360 ONE, Claypond Capital get CCI nod to acquire stakes in API Holdings
Fair trade regulator CCI has approved 360 ONE and Claypond Capital Partners' joint proposal to acquire stakes in API Holdings. This transaction involves purchasing compulsorily convertible preference shares from MEMG Family Office LLP, indicating oversight to prevent unfair business practices and ensure fair competition.
from Healthcare/Biotech-Industry-Economic...